Galimedix, Inc. | Finanzwire

Basculer en Français

10058	Companies
205608	Keywords
135840	Articles
109007	Press releases

Home
Companies
Galimedix, Inc.

BRIEF

published on 03/20/2026 at 08:05, 2 days 5 hours ago

Galimedix Unveils Promising Alzheimer’s Prodrug at AD/PD™ 2026

Galimedix Therapeutics Pharmacokinetic Profile Alzheimer’s Treatment Neuroprotective Therapy Oral Prodrug
PRESS RELEASE

published on 03/20/2026 at 08:00, 2 days 5 hours ago

Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer's candidate at AD/PD™ 2026, demonstrating improved absorption and systemic exposure for patient-friendly dosing

Alzheimer's Disease Galimedix Therapeutics Pharmacokinetic Profile Oral Alzheimer's Candidate AD/PD™ 2026
BRIEF

published on 03/12/2026 at 13:05, 10 days ago

Galimedix Therapeutics Secures Milestone Payment in Partnership with Théa

Galimedix Therapeutics Théa Open Innovation GAL-101 Trials Ophthalmology Partnership Alzheimer's Advancement
PRESS RELEASE

published on 03/12/2026 at 13:00, 10 days ago

Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation, advancing oral therapy for eye diseases and Alzheimer’s

Phase 1 Trial Alzheimer's Disease Galimedix Therapeutics Milestone Payment Ophthalmology Partnership
BRIEF

published on 03/05/2026 at 14:05, 16 days 23 hours ago

Galimedix Therapeutics to Showcase New Amyloid Beta Modulator at AD/PD 2026

Neurodegenerative Disorders Galimedix Therapeutics Pharmacokinetics Amyloid Beta AD/PD 2026 Conference
PRESS RELEASE

published on 03/05/2026 at 14:00, 16 days 23 hours ago

Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
Galimedix Therapeutics to present pre-clinical data on new oral amyloid beta modulator at AD/PD™ 2026 Conference, discussing GAL-201 prodrugs and improved pharmacokinetics

Galimedix Therapeutics Pre-clinical Data Pharmacokinetic Profile Oral Amyloid Beta Modulator AD/PD™ 2026 Conference
BRIEF

published on 12/04/2025 at 20:20, 3 months 17 days ago

Galimedix Therapeutics Reveals Promising Phase 1 Results for GAL-101

Phase 1 Results GAL-101 Alzheimer’s Treatment Blood-brain Barrier Phase 2 Planning
PRESS RELEASE

published on 12/04/2025 at 20:15, 3 months 17 days ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Galimedix Therapeutics presents compelling Phase 1 study results at CTAD 2025, demonstrating excellent safety and pharmacokinetics of GAL-101, planning Phase 2 study in Alzheimer's disease

Alzheimer's Disease Galimedix Therapeutics GAL-101 Phase 1 Study CTAD 2025
BRIEF

published on 09/12/2025 at 13:25, 6 months 9 days ago

Galimedix Advances Alzheimer's Research with Successful Phase 1 Completion

Clinical Trial Galimedix Therapeutics Alzheimer's Research Phase 1 Study GAL-101 Molecule
PRESS RELEASE

published on 09/12/2025 at 13:20, 6 months 9 days ago

Progress in clinical development for Alzheimer´s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modul
Galimedix successfully completes Phase 1 study with GAL-101, a small molecule targeting amyloid beta in Alzheimer's disease. Phase 2 trial planned

Alzheimer's Disease Phase 2 Trial GAL-101 Phase 1 Study Galimedix

Accesswire

Published on 03/20/2026 at 23:00, 1 day 14 hours ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 1 day 15 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 1 day 15 hours ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 1 day 23 hours ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals

View all ACCESSWIRE

EQS Group

Published on 03/22/2026 at 12:23, 44 minutes ago

Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 14 hours ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 16 hours ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 16 hours ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 1 day 16 hours ago

BRP Unveils the Winners of its 6th International Design Challenge

Les Echos

Published on 03/20/2026 at 19:00, 1 day 18 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 1 day 18 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 17:45, 1 day 19 hours ago

Cie du Bois Sauvage : Annual report 2025
Published on 03/20/2026 at 16:57, 1 day 20 hours ago

Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 2 days 19 hours ago

Filing of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE